Cargando…

CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer

BACKGROUND: Prostate cancer progresses slowly when present in low risk forms but can be lethal when it progresses to metastatic disease. A non-invasive test that can detect significant prostate cancer is needed to guide patient management. METHODS: Capillary electrophoresis/mass spectrometry has bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Frantzi, Maria, Gomez Gomez, Enrique, Blanca Pedregosa, Ana, Valero Rosa, José, Latosinska, Agnieszka, Culig, Zoran, Merseburger, Axel S., Luque, Raul M., Requena Tapia, María José, Mischak, Harald, Carrasco Valiente, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738044/
https://www.ncbi.nlm.nih.gov/pubmed/31092909
http://dx.doi.org/10.1038/s41416-019-0472-z
_version_ 1783450770817941504
author Frantzi, Maria
Gomez Gomez, Enrique
Blanca Pedregosa, Ana
Valero Rosa, José
Latosinska, Agnieszka
Culig, Zoran
Merseburger, Axel S.
Luque, Raul M.
Requena Tapia, María José
Mischak, Harald
Carrasco Valiente, Julia
author_facet Frantzi, Maria
Gomez Gomez, Enrique
Blanca Pedregosa, Ana
Valero Rosa, José
Latosinska, Agnieszka
Culig, Zoran
Merseburger, Axel S.
Luque, Raul M.
Requena Tapia, María José
Mischak, Harald
Carrasco Valiente, Julia
author_sort Frantzi, Maria
collection PubMed
description BACKGROUND: Prostate cancer progresses slowly when present in low risk forms but can be lethal when it progresses to metastatic disease. A non-invasive test that can detect significant prostate cancer is needed to guide patient management. METHODS: Capillary electrophoresis/mass spectrometry has been employed to identify urinary peptides that may accurately detect significant prostate cancer. Urine samples from 823 patients with PSA (<15 ng/ml) were collected prior to biopsy. A case–control comparison was performed in a training set of 543 patients (n(Sig) = 98; n(non-Sig) = 445) and a validation set of 280 patients (n(Sig) = 48, n(non-Sig) = 232). Totally, 19 significant peptides were subsequently combined by a support vector machine algorithm. RESULTS: Independent validation of the 19-biomarker model in 280 patients resulted in a 90% sensitivity and 59% specificity, with an AUC of 0.81, outperforming PSA (AUC = 0.58) and the ERSPC-3/4 risk calculator (AUC = 0.69) in the validation set. CONCLUSIONS: This multi-parametric model holds promise to improve the current diagnosis of significant prostate cancer. This test as a guide to biopsy could help to decrease the number of biopsies and guide intervention. Nevertheless, further prospective validation in an external clinical cohort is required to assess the exact performance characteristics.
format Online
Article
Text
id pubmed-6738044
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67380442020-05-16 CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer Frantzi, Maria Gomez Gomez, Enrique Blanca Pedregosa, Ana Valero Rosa, José Latosinska, Agnieszka Culig, Zoran Merseburger, Axel S. Luque, Raul M. Requena Tapia, María José Mischak, Harald Carrasco Valiente, Julia Br J Cancer Article BACKGROUND: Prostate cancer progresses slowly when present in low risk forms but can be lethal when it progresses to metastatic disease. A non-invasive test that can detect significant prostate cancer is needed to guide patient management. METHODS: Capillary electrophoresis/mass spectrometry has been employed to identify urinary peptides that may accurately detect significant prostate cancer. Urine samples from 823 patients with PSA (<15 ng/ml) were collected prior to biopsy. A case–control comparison was performed in a training set of 543 patients (n(Sig) = 98; n(non-Sig) = 445) and a validation set of 280 patients (n(Sig) = 48, n(non-Sig) = 232). Totally, 19 significant peptides were subsequently combined by a support vector machine algorithm. RESULTS: Independent validation of the 19-biomarker model in 280 patients resulted in a 90% sensitivity and 59% specificity, with an AUC of 0.81, outperforming PSA (AUC = 0.58) and the ERSPC-3/4 risk calculator (AUC = 0.69) in the validation set. CONCLUSIONS: This multi-parametric model holds promise to improve the current diagnosis of significant prostate cancer. This test as a guide to biopsy could help to decrease the number of biopsies and guide intervention. Nevertheless, further prospective validation in an external clinical cohort is required to assess the exact performance characteristics. Nature Publishing Group UK 2019-05-16 2019-06-11 /pmc/articles/PMC6738044/ /pubmed/31092909 http://dx.doi.org/10.1038/s41416-019-0472-z Text en © Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Article
Frantzi, Maria
Gomez Gomez, Enrique
Blanca Pedregosa, Ana
Valero Rosa, José
Latosinska, Agnieszka
Culig, Zoran
Merseburger, Axel S.
Luque, Raul M.
Requena Tapia, María José
Mischak, Harald
Carrasco Valiente, Julia
CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
title CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
title_full CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
title_fullStr CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
title_full_unstemmed CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
title_short CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
title_sort ce–ms-based urinary biomarkers to distinguish non-significant from significant prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738044/
https://www.ncbi.nlm.nih.gov/pubmed/31092909
http://dx.doi.org/10.1038/s41416-019-0472-z
work_keys_str_mv AT frantzimaria cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer
AT gomezgomezenrique cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer
AT blancapedregosaana cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer
AT valerorosajose cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer
AT latosinskaagnieszka cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer
AT culigzoran cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer
AT merseburgeraxels cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer
AT luqueraulm cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer
AT requenatapiamariajose cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer
AT mischakharald cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer
AT carrascovalientejulia cemsbasedurinarybiomarkerstodistinguishnonsignificantfromsignificantprostatecancer